Top Quality for Beauty Injections Peptides Follistatin 344

Name: Follistatin 344
Follistatin 344 Specification: 1mg/vial ,10vial/box 
Function: Muscle Growth,together with GHRP, obvious effect.

Synonyms: FST, FS, Activin-binding protein.
Appearance: Sterile Filtered White Lyophilized (Freeze-Dried)
Manufacturer: Quanao
Purity (by HPLC): 99.00%
Source: Escherichia Coli
Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation: Lyophilized from a concentrated (1mg / ml) solution containing no additives.
Solubility: It is recommended to reconstitute the lyophilized Follistatin in sterile 18MΩ-cm H2O not less than 100μg / ml, which can then be further diluted to other aqueous solutions.
Stability: Lyophilized Follistatin although stable at room temperature for 3 weeks.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.
Purity: Greater than 95.0% as determined by (a) Analysis by RP-HPLC (b) Analysis by SDS-PAGE..
Storage Conditions: Aviod Shunshine and Keeping Stoppered
Packing: 1mg / vial, 2mg / vial

How does it work?
It's also worth pointing out that myostatin may have a regulatory role in skeletal muscle fibrosis; too much myostatin can impair tissue function and cause chronic disease in vital organs, tissues, and bone marrow.
In additional to suppressing the degenerative properties of myostatin, follistatin also suppresses the pituitary gland synthesis and secretion of follicle-stimulating hormone (FSH). High FSH levels in men may indicate that testicles are not functioning correctly; this condition limits muscle growth, recovery, and normal hormonal function.
However, FSH levels that are too low can also negatively impact health and reproductive capabilities. Whereas some myostatin inhibitors like Trichostatin A (TSA) require daily administration, increased levels of FS344 were observed up to 15 months after initial injection. The lack of need for daily administration makes follistatin an attractive alternative for suppressing myostatin. The recent increase in attention in the science community on follistatin and other myostatin inhibitors is primarily due to the desire to find an alternative means to treat muscle disorders; the most popular current option is androgen steroids which pose a number of side-effects and long-term health risks. At this point you might be wondering why follistatin use isn't more widespread in bodybuilders and other athletes. In the next section we will examine the current research on follistatin and whether it builds muscle mass.
 
General information above from UniProt
 
GDF-8 / Myostatin / MSTN is a member of the bone morphogenetic protein (BMP) family and the TGF-beta superfamily. This group of proteins is characterized by a polybasic proteolytic processing site which is cleaved to produce a mature protein containing seven conserved cysteine residues. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues. GDF-8 / Myostatin / MSTN is highly expressed in skeletal muscle, and myostatin loss-of-function leads to doubling of skeletal muscle mass. Experiments in mice have improved that GDF-8 / Myostatin / MSTN is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking Myostatin encoding gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. GDF-8 / Myostatin / MSTN is also expressed in the early phases of fracture healing, and GDF-8 / Myostatin / MSTN deficiency leads to increased fracture callus size and strength. Together, these data suggest that GDF-8 / Myostatin / MSTN has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that GDF-8/Myostatin/MSTN antagonists and inhibitors are likely to enhance both muscle mass and bone strength.

 Myostatin-deficient mice have been used as a model for studying muscle-bone interactions, and here we review the skeletal phenotype associated with altered myostatin signaling. It is now known that myostatin is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking the myostatin gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. Myostatin is also expressed in the early phases of fracture healing, and myostatin deficiency leads to increased fracture callus size and strength. Together, these data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength.

 

Peptide  List